Patient distrust in pharmaceutical companies: an explanation for women under-representation in respiratory clinical trials?

Table 2 Multiple (logistic) regression results: crude (cOR) and adjusted (aOR) odds ratios with 95% confidence intervals [95%CI] and associated significance estimates (p-values) for variables used to predict distrust-group membership

	cOR [95%CI]	p-value	aOR [95%CI]	p-value
Age	1.01 [1.00–1.02]	0.040
Gender = male	0.77 [0.59–1.02]	0.064	0.75 [0.56–0.92]	0.042
University = yes	0.92 [0.69–1.23]	0.596
Employment = inactive	1.42 [1.08–1.88]	0.013	1.47 [1.11–1.94]	0.007
Diagnosis
Chronic airway disease	Reference
Interstitial lung disease	1.39 [0.90–2.17]	0.141
Sleep disorders	0.81 [0.52–1.27]	0.019
Other	1.89 [1.21–2.93]	0.377
The patient knows the name of his/her disease	0.67 [0.48–0.93]	0.017	0.64 [0.46–0.90]	0.010
Has already participated in a clinical trial	1.08 [0.79–1.49]	0.625
First consultation for respiratory disease	0.99 [0.69–1.42]	0.976
Inclusion center = public	0.88 [0.64–1.20]	0.406

ISSN: 1472-6939